Showing results (151-160 of 253) with videos related to

Sort By:
Pageof 26
Molecular Cancer Therapeutics|March 17, 2026
A bispecific anti-fluorescein x anti-CD3 T-cell engager in combination with fluoresceinated adaptors enables lysis of AML cellsLaura G Volta, Celeste Gobbi, Christian Koch, et al.
Molecular Cancer Therapeutics|May 11, 2026
A Bispecific Anti-Fluorescein × Anti-CD3 T-cell Engager in Combination with Fluoresceinated Adaptors Enables Lysis of AML CellsLaura G Volta, Celeste Gobbi, Christian Koch, et al.
Nature Biotechnology|March 18, 2014
Development and function of human innate immune cells in a humanized mouse modelAnthony Rongvaux, Tim Willinger, Jan Martinek, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 26, 2011
Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivoAnthony Rongvaux, Tim Willinger, Hitoshi Takizawa, et al.
Blood Advances|December 5, 2024
Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AMLChristian M Vonk, Tim Grob, Melissa Rijken, et al.
EMBO Molecular Medicine|November 9, 2013
Fas (CD95) expression in myeloid cells promotes obesity‐induced muscle insulin resistanceStephan Wueest, Rouven Mueller, Matthias Blüher, et al.
Molecular Therapy Oncolytics|August 16, 2023
Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cellsChiara F Magnani, Renier Myburgh, Silvan Brunn, et al.
The Journal of Experimental Medicine|October 28, 2021
Chronic viral infections persistently alter marrow stroma and impair hematopoietic stem cell fitnessStephan Isringhausen, YeVin Mun, Larisa Kovtonyuk, et al.
Nature Cancer|April 20, 2023
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myelomaKlara Kropivsek, Paul Kachel, Sandra Goetze, et al.
Journal for Immunotherapy of Cancer|August 14, 2024
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockadeCesare Di Nitto, Domenico Ravazza, Ettore Gilardoni, et al.
Pageof 26